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1st Editorial Decision 24 March 2012 
 
Thank you for the submission of your manuscript to EMBO Molecular Medicine. We have now 
heard back from the three referees whom we asked to evaluate your manuscript.  
 
Although the referees find the topic of the study important, they also raise a number of substantial 
concerns about the conclusiveness of the results and technical issues, which should be convincingly 
addressed in a major revision of the current mnanuscript.  
 
As you will see from the enclosed reports, the article should be streamlined to clarify the message as 
suggested by both referees 1 and 3. All three reviewers are concerned with lack of controls, lack of 
or inappropriate statistical analysis, and unconvincing experiments. They do suggest, however, ways 
of improving the manuscript that would involve a lot of additional (experimental) work. I am 
uncertain whether you will be able (or willing) to return a revised manuscript within the 3 months 
deadline and I would understand your decision if you choose to rather seek rapid publication 
elsewhere.  
 
Nonetheless, while it is clear that publication of the paper cannot be considered at this stage, I would 
be open to the submission of a revised manuscript providing that the referees' concerns must be fully 
addressed and that acceptance of the manuscript would entail a second round of review. I would add 
that it is particularly important that all of their suggestions are taken on board as we cannot consider 
its publication otherwise.  
 
I should remind you that it is EMBO Molecular Medicine policy to allow a single round of revision 
only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness 
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 of your responses included in the next, final version of the manuscript.  
 
I look forward to seeing a revised form of your manuscript as soon as possible.  
 
Should you find that the requested revisions are not feasible within the constraints outlined here and 
choose, therefore, to submit your paper elsewhere, we would welcome a message to this effect.  
 
 
Yours sincerely,  
 
Editor  
EMBO Molecular Medicine  
 
***** Reviewer's comments *****  
 
Referee #1 (Other Remarks):  
 
In this manuscript, Wend et al provide evidence that transgenic murine WNT10B-driven tumors 
resemble human triple negative breast cancers. The authors suggest that WNT10B signaling 
activates beta-catenin leading to HMGA2 upregulation and proliferation. They go on to suggest that 
this observation applies to CD44+ cells, which is one of the known self-renewal markers in 
mammary epithelial cells. Finally, the authors use a chemical inhibitor of Wnt/B-catenin pathway to 
validate some of their findings. Identifying mouse models that mimic triple negative breast cancer is 
of interest given its current absence. The mechanisms that contribute to the triple negative breast 
cancer phenotype have been the center of much attention since this could be pivotal to tackle this 
aggressive disease.  
 
This manuscript identifies an interesting model that could serve the study of triple negative breast 
cancer in the mouse and the description is largely convincing. However, this represents and 
incremental but not a substantial advance since the mechanistic analysis and the phenotypic 
explanations are rather confusing, not hypothesis driven and lack of important controls and gaps.  
 
Major Points:  
 
1. The manuscript is a collection of evidences, with important gaps that need to be filled. First, the 
authors show that when ER negative (not triple negative) breast cancer primary tumors are separate 
according to WNT10A mRNA levels but not WNT1 these two groups behave differently in terms of 
relapse (log rank test). It is not clear whether ERnegative patients that express WNT10b are TNBC 
or not. In turn, the authors, based on a small series of IHC analysis, suggest that protein levels exert 
this function and, in turn, this is specific of triple negative breast cancer. Unfortunately, no statistics 
are draw. Then the authors describe a transgenic mouse model that express WNT10b. These mice 
develop mammary tumors that resemble TNBC. This is an interesting observation, however how 
does WNT10b generate this phenotype is not clear at all. The authors suggest is via HMGA2, but do 
not show how. Moreover, they claim that HMGA2 triggers a self-renewal phenotype and more 
proliferation but they do not show what is the relationship with the TNBC. Overall, the message is 
not clear, the reader gets confused and no mechanistic link between WNT10b, signaling, expression 
of HMG2A and contribution of HMG2A to TNBC phenotype is observed. The authors need to make 
an important effort to streamline these points, connect them and provide data that fills the gaps.  
 
2. The authors' state (page 4, third paragraph) based on the literature that 50% of breast cancers have 
nuclear b-catenin. However, when they analyze their patient sample series, they restrict WNT10b to 
a small subset of TNBC samples. They go on and attribute to tumors that express WNT10b TNBC 
properties. However, if 50% of breast cancer tumors have nuclear b-catenin in the nucleus (meaning 
Wnt signaling is ongoing) and >60% of breast cancer patients are ER+, it is unlikely that WNT10b 
through Wnt signaling leads to TNBC in a representative cohort of breast cancer patients. Indeed, 
this suggests that Wnt signaling (nuclear b-catenin) is not responsible for the TNBC phenotype and 
that other things, possibly downstream of WNT10b, are more relevant to establish such phenotype. 
The key point is what is responsible for TNBC independently of Wnt-signaling. A question that the 
authors do not address. Moreover, this point questions their transgenic mice model. Thus, prompting 
for the request to induce MMTV-WNT10b driven expression in a different genetic background to 
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 confirm their observation.  
 
3. As highlighted before, the authors should include data referring to the additional 24 TNBC 
samples from the cohorts from LA and Chicago. Moreover, statistics depicting the correlation 
between nuclear b-catenin and Wnt10b should be draw. Finally, a comparison with other breast 
cancer tumors subtypes is also necessary. It must be shown whether this correlation is unique of 
TNBC or it also occurs in other breast cancer subtypes (plus statistics).  
 
4. Again, association between CD44 and TNBC markers (including nuclear b-catenin) lacks 
statistics. Significance is missing and without it no claims can be made. Similarly, this applies for 
WNT10b and AXIN2.  
 
5. Page 8, second paragraph. The authors state that WNT10b expression was validated to be high in 
TNBC. The authors should stick with the data. The data depicted indicates that WNT10b is relevant 
in ER negative breast cancer but not in TNBC (the latter is included in the earlier). Finally, since the 
authors claim prediction of risk, COX proportional hazard analysis instead of Log Rank test should 
be performed.  
 
6. The authors identify WNT10b as a potential marker of TNBC. How is it accumulated, expressed 
of induced in TNBC tumors?  
 
7. The authors claim that MMTV-WNT10b mice BC tumors are enriched for cells with high self-
renewal potential. Surprisingly, they define tumor-initiating cells (page 9, 2nd paragraph) as 
CD44high, CD24low. However, through their manuscript they only focus on CD44high, CD24 high. 
How come? A very convincing explanation must be provided. Clearly, their statement in page 22 
and 23 of the discussion does not help, 2 out of the 3 arguments provided highlight the importance 
of CD24low for aggressiveness and stemnes.  
 
8. The authors claim that the self-renewal marker HMGA2 is expressed and provides self-renewal 
functions. However, in figure 3b it can be observed how unsorted cells expressed higher levels of 
HMGA2 than tumor initiating cells. Thus, the stem cell population does not experience the higher 
induction of this gene. These results suggest that this protein might be necessary but not sufficient to 
explain this WNT10b driven phenotype. On top of that, how does WNT10b regulate HMGA2?  
 
9. Inhibitors are very dangerous toys. They are accompanied with uncontrolled side effects. Thus, 
the authors must use and independent compound that targets the same principle to ensure robustness. 
Alternative, they could use a b-catenin shorthairpin construct to validate some of their key 
experiments.  
 
10. Page 16, first paragraph. In figure 5 the authors use ICG-001 to block b-catenin signaling and 
test downregulation of HMGA2, CyclinA2 etc... The question is: what does happen in MCF710b 
cells? This is of particular interest given in these cells all nuclear b-catenin signaling is, in principle, 
generated by WNT10b.  
 
11. The authors used the MDA-MB-231 cells to test whether ICG-100 cause an induction of INK4 
locus CDK inhibitors. These results are puzzling, particularly because there are several reports in the 
literature claiming that these breast cancer cells are INK4 locus deleted (i.e Bisonga et al Cancer 
Genetics and Cytogenetics 125 (2001) 131-138 and others). This locus includes p16, p19 and p15. 
Thus it is very strange that the authors do not observe activation of p16 and p19 but observe 
activation of p15. Given the literature reports, the authors must verify that their MDA-MB231 cells 
have an intact INK4 locus (including INK4b).  
 
12. To determine if HMGA2 is necessary and sufficient for proliferation of MDA-231 cells 
downstream of WNT10b, the authors should test if WNT10b exogenous expression effect is 
completely abolished by shHMGA2.  
 
13. Given the same sample set was used to evaluate the differences in disease-free survival between 
groups that express low and high WNT10b and HMG2A, a correlation between the expression of 
both genes and its significance should be draw as this is pivotal to the authors claims.  
 










Referee #2 (Other Remarks):  
 
The triple negative breast cancer (TNBC) lacks targeted therapy. Identifying the critical pathways 
driving the growth of this type of breast cancers is a high priority in the breast cancer research field. 
The important role of the Wnt pathway in some of the TNBC has been implicated in several studies 
published in the past few years. The authors in the manuscript tried to demonstrate that the mouse 
MMTV-Wnt10B mammary tumor model mimics human TNBC. They further attempted to link the 
Wnt10B-induced canonical Wnt pathway to HMGA2 expression and the proliferation of cancer 
stem cells which they believed to be the CD44+ CD24+ cells. While the issue that the authors tried 
to address is important, the data presented are not convinicng or lack proper controls. Some of the 
concerns are listed below:  
 
1. The authors concluded that WNT10B was strongly expressed in >60% TNBC based on IHC using 
a WNT10B antibody from Abcam (page 7 and Supplemental Material and Methods). The authors 
stated that that was the first time that WNT10B was detected in primary human breast tumors by 
IHC (page22). There are four antibodies against WNT10B from Abcam: ab70816, ab105860, 
ab66721, and ab91201 (http://www.abcam.com/index.html?pageconfig=searchresults). Based on the 
company's website, both ab70816 and ab105860 recognize some unknown proteins based on 
Western blot, especially at 47kDa and 93kDa regions, making them less specific to WNT10B. The 
ab66721 work for ICC (immunocytochemistry) but not IHC; and the ab91201 IHC staining signal is 
located outside the cells in several tissues, which is significantly different from the staining pattern 
seen in this manuscript. For these reasons, the detail information of the antibody used in this study 
and the positive/negative controls are critical for evaluating the result. Unfortunately, neigher the 
specific antibody information nor the positive and negative controls can be found in this manuscript, 
making it difficult to evaluate the result. Furthermore, based on the Oncomine search, there is no 
significant difference of the WNT10B expression level between TNBC and non-TNBC. Therefore, 
the staining status of WNT10B in non-TNBC samples should be presented to show whether 
WNT10B is specifically expressed in the TNBC. This oncomine analysis should be discussed.  
 
2. The authors claimed that the LacZ+CD44+CD24+ cells in the Wnt10bLacZ mammary tumor are 
a "stem-cell population" (page 11 and other pages). This claim lacks critical evidence. The limiting 
dilution transplantation assay is the only accepted method to demonstrate that a specific cell 
population is a stem cell population. This assay needs the transplantation of both the proposed stem 
cell population and the non-stem cell population. Only when the proposed stem cell population gives 
rise to tumor growth at a significantly higher frequecy than the non-stem-cell population, the 
proposed stem cell population can be concluded to be a stem cell-enriched population. 
Unfortunately, the authors only transplanted the LacZ+CD44+CD24+ cells without including the 
non-LacZ+CD44+CD24+ cell transplantation comparison.  
 
3. The authors demonstrated that the Wnt10b-driven tumors are TN tumors by showing ER, PR and 
Erbb2 negativity using qt-PCR (Fig2 and S3). Because the autors used pregnant mammary gland as 
a posittive contol, the relatively low mRNA level of ER or PR in the Wnt10b-driven tumors does 
not necessaryly mean that these tumors are ER/PR negative. IHC-based scoring on these tumors is 
necessary to evaluate whether these tumors are ER/PR negative. A similar problem is also true for 
concluding HER2 negativity.  
 
4. The authors tried to demonstrate "nuclear HMGA2 expression is restricted to TNBC as it was not 
detectable in ER-α+, PR+, Her2+ and TP breast cancer samples (Fig.6B)" (page 19). While they 
stated that 38 TNBC samples were used to demonstrate that greater more than 80% of them were 
positive for nuclear HMGA2, they did not show how many ER-α+, PR+, Her2+ and TP breast 
cancer samples were used for comparison. This is a very important concern because the Oncomine 
TCGA microarray data show no significant difference of the HMGA2 expression level between the 
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 TNBC and non-TNBC. There are many microarray datasets available in the Oncomine. Instead of 
chosing the large datasets such as the TCGA breast, the authors chose the relatively small dataset of 
Richardson to conclude that "HMGA2 is highly and specifically expressed in triple-negative (ER-
PR-ErbB2-) human breast cancer". However, even in this dataset, the difference of HMGA2 
expression between the TNBC and non-TNBC is not significant. Therefore, the authors' presentation 
of the analysis of public datasets was misleading.  
 
5. Staining for nucleare β-catenin, axin2, CK6 is not convincing.  
 
6. On page 3, the authors described "These breast cancers are divided into six subtypes that are 
highly heterogeneous both histologically (Weigelt & Reis-Filho, 2009) and by gene expression 
profiling (Perou et al, 2000; Sorlie et al, 2003): luminal A, luminal B, ERBB2/HER2, normal breast-
like, basal-like and triple-negative (TN)." The terms used in the IHC-based clinical clasification and 
the microassay-based clasification should not be mixed together.  
 
7. CD61 and Sca1 are not MaSC marker (page 8).  
 
8. The rationale of the comparison of mammosphere-forming frequency between normal mammary 
gland cells and tumor cells is not clear (page 12).  
 




Referee #3 (Other Remarks):  
 
The manuscript by Wend et al. reports on the role of Wnt signalling in triple negative breast cancer 
by making use of interesting mouse models and of primary human material. Overall, I found that, 
although it relies on previous evidence on the role of Wnt in TNBC and as such it is not entirely 
novel, it contains several advancements in our knowledge of the underlying cellular and molecular 
mechanisms and in particular on the role played by WNT10B as a ligand and of HMGA2 as a 
downstream effector. Having said that, the manuscript is excessively long as it encompasses a rather 
extensive body of experimental evidence presented in a confusing fashion that makes it extremely 
difficult for the reader to go through. Also, too often statements are based on "data not shown" and 
the rationale for a number of experiments has not been explained. In view of this, I'd propose major 
revision of the manuscript along the lines of my specific comments listed here below.  
 
1. Page 6-7. The panel of 14 (German) and 24 (US) primary TNBCs samples is rather limited and, 
ideally, larger cohorts should be employed to validate the observations on WNT10B expression. 
Also, the evidence relative to cells earmarked by nuclear beta-catenin localization is central to this 
manuscript but is, somewhat surprisingly, not presented (data not shown). The IHC images 
presented in Fig. 1A, especially with Ab's directed against beta-catenin are not convincing and 
nuclear beta-catenin is not evident. As it is generally known, IHC analysis of beta-catenin 
subcellular localization is tricky and antigen retrieval protocol based on neutral pH should be 
preferred. From the images in my possession, strong (overstained?) cytoplasmatic staining is seen 
which makes it difficult to evaluate nuclear expression. The IF-based evidence for the co-
localization of nuclear beta-cat with basal epithelial markers and CD44 (Fig. S1B-C) is also not very 
convincing and again this might be due to the poor graphic resolution of the figures in my pdf file. 
Also, CD44 is here mentioned as a "stem cell marker" with no references to back this up. To the best 
of my knowledge, although there are reports on the use of CD44 to enrich (cancer) stem cells (when 
combined with other CD markers) in specific tissues, CD44 is more often expressed in progenitor 
cells.  
 
2. Pages 7-8. I admittedly am not an expert on this but the data relative to WNT10B as a predictor of 
survival outcome (Fig. 1C-D) do not appear to be very strong. Again, important data to support this 
concept (LRP6 as a predictor and the specificity of WNT10B for TNBC but not for ER-a-positive 
breast cancers is stated but not presented (data not shown). Overall, the conclusive paragraph at page 
8 contains a number of rather hard conclusions which are not entirely supported by the experimental 
evidence (also the evidence relative to AXIN2 expression is not particularly convincing (Fig. 1A; 
also in view of the scarcity of specific Ab's capable of recognizing AXIN2 in IHC) and which 
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 should be tempered.  
 
3. Page 8-9. To analyse the expression of MaSC markers in Wnt10b-driven tumors qt-PCR and IHC 
(again as data not shown) analysis is employed. However, the markers employed were originally 
found to enrich for MaSCs primarily by FACS analysis when employed in specific combinations 
(e.g. CD29hiCD24+). As such, it is difficult to interpret the significance of these results. Instead, I 
would have expected a thorough FACS analysis of these mouse tumors coupled with limiting 
dilution transplantation assays in immune-deficient or syngeneic hosts. Also, the sentence on 
CD44+CD24-/low in human TNBC (page 9) appears as "out of the blue" and not so relevant to this 
section of the result. In general, these type of comments which entirely rely on previous literature 
should be confined to the Discussion section.  
The transplantation assays performed with Lin-Lacz+ tumour cells have been performed with 
extremely high number of cells (Fig. S2B-C; >0.5*106) and are not informative relative to their 
identity as CSCs or tumour-initiating cells. Also in this case, the data relative to 
Lacz+CD44hiCD24hi transplantation are not shown and it is not clear what the rationale was to 
prefer this specific combination of CD markers to others previously demonstrated to encompass 
CSCs in Wnt-driven tumors (e.g. CD29hiCD24+).  
 
4. Page 10. To characterize (quantify?) Lacz+CD44hiCD24hi tumor cells, FACS analysis was 
employed (Fig. 2D). This part is unclearly written and I had difficulties in understanding what was 
actually done. The figure shows 3 distinct FACS panels relative to Lin-Lacz+ (tumour) cells (i.e. not 
Lacz+CD44hiCD24hi as stated in the text) with no indication to what they represent (not even in the 
legend). From the text, with some guessing, one infers that, from left to right, they show normal 
mammary gland cells from wild type and a transgenic Wnt10bLacz mice, and tumour cells from 
Wnt10b-driven tumors. Provided my interpretation is correct, it is not clear what the significance of 
these analyses is in the absence of transplantation assays (at limiting cell multiplicities) for each of 
these subpopulations. Once again, the rationale for the choice of CD24 and CD44 instead of other 
previously established combinations of CD markers is unclear.  
In the last paragraph, it is stated that the expression of specific Wnt targets was in fact lower in 
Lacz+CD44hiCD24hi tumor cells when compared with Lacz+ and bulk tumour cells. This is 
surprising as it indicates a lower level of Wnt signalling in the alleged CSC population. These data 
should be confirmed by Wnt reporter assays rather than by evaluation of few downstream targets. 
This is also partly contradictory with the co-localization of these stem cell markers and nuclear beta-
catenin.  
 
5. Page 11. When it comes to Hmga2 expression, it is notable that this is highest in the bulk 
(unsorted) tumour cells when compared to all other subpopulations. Again, this questions the 
relationship between Wnt signalling, nuclear beta-cat and cancer stemness, also in relation to 
Hmga2 expression. Notably, Hmga1 is mostly expressed in Lacz+CD44hiCD24hi tumor cells but 
this observation is somewhat left unnoticed and is not followed up any further. From this 
perspective, the conclusive statement of this paragraph according to which Hmga1 and Hmga2 
expression is increased in the stem-cell population is true only for the former but not for the latter.  
 
6. Page 12. The mammosphere assays were performed with bulk tumour (and normal) cells and as 
such are not very informative. Preferably, FACSorted subpopulations of tumour cells should have 
been employed under controlled experimental conditions (limiting cell multiplicities in matrigel).  
 
7. Page 19. The data relative to the high (>80%) frequency of nuclear HMGA2 expression in 
TNBCs is again presented as "data not shown". Also, it is said that many of these TNBC were in 
fact metaplastic breast cancers and as evidence for that H&E staining is presented (Fig. 6A and SA-
C). Metaplasia should be confirmed by IHC with specific markers for squamous or other 
"illegitimate" differentiation lineages. To the best of my capacity to analyse the figures (with the 
previously mentioned limitation of the poor graphic resolution) the images do not support this.  
 
8. Pages 21-25. In view of my general introductory comments, the lengthy discussion should be 
shortened considerably.  
 
9. Page 23. "...we also provide evidence that Wnt10b-driven tumors are highly enriched in 
Lacz+CD44hiCD24hi cells that have cancer-initiating capacity when serially passaged in syngeneic 
mice (data not shown)". These data are indeed not shown throughout the manuscript and as such the 
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 authors cannot make this claim! Likewise, self-renewal assays (repeated cycles of CSC sorting by 
FACS, their transplantation at limiting dilution thus demonstrating not only their self-renewal but 
also their capacity to differentiate and recapitulate the primary tumors) were never formally 
performed. In this page, self-renewal of CD44+ cells (?) is implied but was never shown. Likewise, 
in the follow-up of this discussion, it is suggested that CD44+ cells from TNBC tumors may be 
enriched in CSCs but the evidence for this is limited to immortalized cell lines resembling TNBC 
and not to primary patient material.  
Overall, I believe that the evidence relative to WNT10B and HMGA2 expression and their 
downstream effectors in mouse and human TNBCs is novel and of general interest. However, when 
it comes to cancer stemness, its relationship with Wnt signalling, and the identification of a specific 
subpopulation of TNBC cells the evidence is much weaker and in part simply not shown or not 
appropriately performed. Given the value of the data on the functional role of to WNT10B and 
HMGA2 expression in TNBC, I would have preferred a shorter and easier to read manuscript with 
focus on these two genes, independently from the cancer stem cell aspects which are clearly less 







1st Revision - authors' response 07 August 2012 
 
(please see next page)   
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General response to all reviewers: 
We would like to thank the reviewers for their critical and insightful reviews of our manuscript.  
We have made a major revision of the manuscript to address the major concerns raised.  We have also 
removed whole sections from our previously submitted manuscript, based on the recommendation from 
the reviewers.  Additionally, we have worked rigorously to stream line our story and focused on the 
editing of the MS for easier reading and focused our discussion on how WNT10b regulates HMGA2 and 
its role on proliferation.  We have removed almost 10,000 characters from the text to achieve your 
recommendations. Please find the point-by-point responses to the critiques. 
 
***** Reviewer's comments *****  
 
 Referee #1 (Other Remarks):  
In this manuscript, Wend et al provide evidence that transgenic murine WNT10B-driven tumors resemble 
human triple negative breast cancers. The authors suggest that WNT10B signaling activates beta-catenin 
leading to HMGA2 upregulation and proliferation. They go on to suggest that this observation applies to 
CD44+ cells, which is one of the known self-renewal markers in mammary epithelial cells. Finally, the 
authors use a chemical inhibitor of Wnt/B-catenin pathway to validate some of their findings. Identifying 
mouse models that mimic triple negative breast cancer is of interest given its current absence. The 
mechanisms that contribute to the triple negative breast cancer phenotype have been the center of much 
attention since this could be pivotal to tackle this aggressive disease.  
  
This manuscript identifies an interesting model that could serve the study of triple negative breast cancer 
in the mouse and the description is largely convincing. However, this represents and incremental but not a 
substantial advance since the mechanistic analysis and the phenotypic explanations are rather confusing, 
not hypothesis driven and lack of important controls and gaps.  
  
Major Points:  
  
1. The manuscript is a collection of evidences, with important gaps that need to be filled. First, the authors 
show that when ER negative (not triple negative) breast cancer primary tumors are separate according to 
WNT10A mRNA levels but not WNT1 these two groups behave differently in terms of relapse (log rank 
test). It is not clear whether ER negative patients that express WNT10b are TNBC or not. In turn, the 
authors, based on a small series of IHC analysis, suggest that protein levels exert this function and, in 
turn, this is specific of triple negative breast cancer. Unfortunately, no statistics are draw. Then the 
authors describe a transgenic mouse model that express WNT10b. These mice develop mammary tumors 
that resemble TNBC. This is an interesting observation, however how does WNT10b generate this 
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phenotype is not clear at all. The authors suggest is via HMGA2, but do not show how. Moreover, they 
claim that HMGA2 triggers a self-renewal phenotype and more proliferation but they do not show what is 
the relationship with the TNBC. Overall, the message is not clear, the reader gets confused and no 
mechanistic link between WNT10b, signaling, expression of HMG2A and contribution of HMG2A to 
TNBC phenotype is observed. The authors need to make an important effort to streamline these points, 
connect them and provide data that fills the gaps.  
  
1) “It is not clear whether ER negative patients that express WNT10b are TNBC or not. In turn, the 
authors, based on a small series of IHC analysis, suggest that protein levels exert this function and, in 
turn, this is specific of triple negative breast cancer. Unfortunately, no statistics are draw.” 
Point by point response:  We have a new Figure 1 which now allows for the assessment of the WNT10B 
antibody on a set of TMAs. We have quantitated the results.  We show new survival curves from basal-
like cancer and illustrate that WNT10B has predictive value (KM-plotter).  We have also finished our 
analysis on 59 TNBC samples illustrating that WNT10B has predictive value for two categories: tumor 
size and nuclear grade  with significant statistics (p=0.021 and p=0.025).  
i) “Then the authors describe a transgenic mouse model that express WNT10b. These mice 
develop mammary tumors that resemble TNBC. This is an interesting observation, however how does 
WNT10b generate this phenotype is not clear at all. The authors suggest is via HMGA2, but do not show 
how”. 
Point by point response:  We illustrate that Wnt10bLacZ-driven tumors are devoid of ER, PR and HER2 
protein expression connecting our model better to TNBC in the text. We have now addressed mechanistic 
questions on how we think HMGA2 contributes to our model and Figure 2-3 show new data.  i) We 
illustrate that HMGA2 expression is lost in Wnt10B-knockout (Wnt10bKO) mice in early embryogenesis 
in the mammary anlagen ii) We illustrate evidence that beta-catenin directly ChIP’s to the HMAG2 
promoter and our new biochemical data show that it requires CBP interactions.  iii) Silencing of HMGA2 
leads to a block in proliferation in both mouse mammary gland cell lines and a tumor-derived cell line.   
2) “Moreover, they claim that HMGA2 triggers a self-renewal phenotype and more proliferation but they 
do not show what is the relationship with the TNBC…” 
Point by point response:  Based on the critique we have removed much of the self-renewal references 
from the MS as we realized that we lack experimental support. We now focus on “self-renewal” to 
compare cells from wildtype vs. Wnt10bKO vs. WNt10bLacZ mice for the capacity to generate 
mammospheres over a 30 days period (Fig. 2 F-G).  
2. The authors' state (page 4, third paragraph) based on the literature that 50% of breast cancers have 
nuclear b-catenin. However, when they analyze their patient sample series, they restrict WNT10b to a 
small subset of TNBC samples. They go on and attribute to tumors that express WNT10b TNBC 
properties. However, if 50% of breast cancer tumors have nuclear b-catenin in the nucleus (meaning Wnt 
signaling is ongoing) and >60% of breast cancer patients are ER+, it is unlikely that WNT10b through 
Wnt signaling leads to TNBC in a representative cohort of breast cancer patients. Indeed, this suggests 
that Wnt signaling (nuclear b-catenin) is not responsible for the TNBC phenotype and that other things, 
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possibly downstream of WNT10b, are more relevant to establish such phenotype. The key point is what is 
responsible for TNBC independently of Wnt-signaling. A question that the authors do not address. 
Moreover, this point questions their transgenic mice model. Thus, prompting for the request to induce 
MMTV-WNT10b driven expression in a different genetic background to confirm their observation.  
Point by point response:  We thank the reviewer for the critique.  We understand the controversy over 
the relevance of beta-catenin in breast cancer (why is not always nuclear). 
a) We have corrected the paragraph in question and changed it to “… ß-catenin is upregulated in 
more than 50% of breast cancer cases  (Cowin et al, 2005)…” and removed “nuclear”. We apologize for 
the over statement; it was an error when editing and it now reflects what is known in the field. 
b) We hope that new data Fig. 1A-B and Supplemental Fig. S1A-B clarifies our results and 
statement.  We have attempted to show the correlation of WNT10B in similar regions as that of beta-
catenin and have conducted both in situ hybridization (ISH) and immunohistochemistry (IHC) for 
AXIN2, a well-known beta-catenin direct target gene. Furthermore, we illustrate that we have active gene 
expression of the Wnt pathway in our TNBC cases.  This suggests that even though beta-catenin does not 
always look nuclear it can still activate transcription of its target genes (e.g. Axin2). We have also added 
new data on nuclear -catenin that corresponds to AXIN2 expression (Suppl. Fig. S1C, D). Also illustrate 
additional -catenin IHC supplemental Fig. S8. 
c) We could not generate a new genetic mouse model (e.g. in a different genetic background) in 
the time for the revision of this manuscript.  But we did conduct IHC for ER-PR and 
HER2Wnt10bLacZ-induced tumors and they were negative illustrating their TN phenotype.  We now also 
provide positive control staining for tissues such as mouse uterus and ErbB2 tumor. 
 3. As highlighted before, the authors should include data referring to the additional 24 TNBC samples 
from the cohorts from LA and Chicago. Moreover, statistics depicting the correlation between nuclear b-
catenin and Wnt10b should be draw. Finally, a comparison with other breast cancer tumors subtypes is 
also necessary. It must be shown whether this correlation is unique of TNBC or it also occurs in other 
breast cancer subtypes (plus statistics).  
Point by point response:  We thank the reviewer for the valuable critique. We have addressed the 
WNT10B comparison to tissue from other breast cancer subtypes by analyzing 125 samples from 
commercially available tissue microarrays (TMA) and illustrate several samples for TN, ER+ PR+ and 
Her2+ breast tumors.  Our pathologists have quantified the results (Fig. 1B).  We provide a new table for 
the tumors (Supplemental Table 1) and depict the statistics in supplemental Fig S7.  
Reviewer comments:   “Moreover, statistics depicting the correlation between nuclear b-catenin and 
Wnt10b should be draw” 
Point by point response:  We thank you for this valuable recommendation.  We would like to respond to 
this point by provide data only for the reviewers eyes by showing the data but not including in the 
manuscript as it is planned to be used for another ongoing project.  'DWDQRWVKRZQLQWKLV3HHU5HYLHZ
3URFHVVILOH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4. Again, association between CD44 and TNBC markers (including nuclear b-catenin) lacks 
statistics. Significance is missing and without it no claims can be made. Similarly, this applies for 
WNT10b and AXIN2. 
 
 
Point by point response: We have removed all data for CD44 and nuclear b-catenin co-staining 
to stream line and shorten the MS. We apologize but we did not have time to conduct statistics on 
AXIN2 because we need to cover over 180 samples to do this. We lacked the time and resources 
to meet this critique. But we did conduct ISH and IHC for AXIN2 in over 14 samples (i.e. 





(Continued on next page.) 
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5. Page 8, second paragraph. The authors state that WNT10b expression was validated to be high in 
TNBC. The authors should stick with the data. The data depicted indicates that WNT10b is relevant in ER 
negative breast cancer but not in TNBC (the latter is included in the earlier). Finally, since the authors 
claim prediction of risk, COX proportional hazard analysis instead of Log Rank test should be performed.  
Point by point response:  We have addressed the reviewer’s concerns as follows: 
i) During the revision we have conducted a completely new analysis of TNBC patient 
material showing the significant correlation between high WNT10B expression and poor 
clinical outcome, such as tumor size and nuclear grade (Fig. 1D). 
ii) We have added the basal-like data from the KM-plotter showing that WNT10B is 
relevant (Fig. 1E) but in contrast WNT1 is not. 
iii) The hazard ratio (and the corresponding 95% confidence interval) was in fact estimated 
using Cox’s proportional hazard model. The hazard ratios are depicted in the KM 
survival curves (HR, upper right in the diagram). The score test of the proportional 
hazard model is equivalent to the log-rank test. 
iv) We also added the following in the text: “Remarkably, WNT10B was able to predict 
survival outcome, time-to-event curves analyzed by Cox proportional hazards regression 
analysis generated a hazard ratio (HR) of 1.38 (p=0.038)” to paragraph 2 page 8.  
7. The authors claim that MMTV-WNT10b mice BC tumors are enriched for cells with high self-renewal 
potential. Surprisingly, they define tumor-initiating cells (page 9, 2nd paragraph) as CD44high, CD24low. 
However, through their manuscript they only focus on CD44high, CD24 high. How come? A very 
convincing explanation must be provided. Clearly, their statement in page 22 and 23 of the discussion 
does not help, 2 out of the 3 arguments provided highlight the importance of CD24low for aggressiveness 
and stemnes.  
Point by point response:  We thank the reviewer for these thoughts and we agree that this section still 
requires much more work and it is still very preliminary at best to be published.  Therefore, we have 
completely removed the figure and all references to CD44 and CD24 markers and stemness.   
 
8. The authors claim that the self-renewal marker HMGA2 is expressed and provides self-renewal 
functions. However, in figure 3b it can be observed how unsorted cells expressed higher levels of 
HMGA2 than tumor initiating cells. Thus, the stem cell population does not experience the higher 
induction of this gene. These results suggest that this protein might be necessary but not sufficient to 
explain this WNT10b driven phenotype. On top of that, how does WNT10b regulate HMGA2?  
Point by point response:  We have completely revised Figure 3 and focused our comments and 
interpretations to the mechanism by which WNT10b regulates Hmga2. 
i) We removed references in the text and figures about HMGA2 as a self-renewal marker. 
ii) We illustrate that WNT10b can induce Hmga2 expression in a normal mouse cell line 
NuMG.  More importantly we provide the mechanism of action to be beta-catenin/CBP 
dependent (Fig. 3B-C) and that cell proliferation is affected after shRNA-mediated 
knockdown of Hmga2 in the presence of WNT10B (Suppl. Fig. S3).  
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iii) We have silenced Hmga2 expression in tumor-derived cell lines and block proliferation. 
iv) We have inhibited sphere formation of primary tumor cells with both Wnt-ligand 
inhibitor (Wnt-C59) and ICG-001 to disrupt nuclear beta-catenin activity. (Fig. 3 H,J). 
  
9. Inhibitors are very dangerous toys. They are accompanied with uncontrolled side effects. Thus, the 
authors must use and independent compound that targets the same principle to ensure robustness. 
Alternative, they could use a b-catenin shorthairpin construct to validate some of their key experiments.  
Point by point response:  We agree and thank the reviewer for this comment. 
We have now addressed this concern several times in the MS by also testing our model to exposure to 
Wnt-C59 (a Porcupine inhibitor like IWSP 2, 3 and 4), which blocks secretion of Wnt ligands. We have 
compared the effects of Wnt-C59 directly to ICG-001 (Fig. 3J and Fig. 4F). The results measured for 
Wnt-C59 are very similar to those induced by ICG-001.
10. Page 16, first paragraph. In figure 5 the authors use ICG-001 to block b-catenin signaling and test 
downregulation of HMGA2, CyclinA2 etc... The question is: what does happen in MCF710b cells? This 
is of particular interest given in these cells all nuclear b-catenin signaling is, in principle, generated by 
WNT10b.  
Point by point response: We have addressed this concern in Supplemental Fig. S4B-C.  To the text we 
added the following 
i)  Moreover, HMGA2 is not responsive to 17-estradiol (E2) treatment of parental MCF7 
cells or in MCF7-10b cells; MCF7-10b cells are still responsive to E2 treatment by upregulation of XBP1 
and pS2 and express known canonical Wnt-signaling target genes, such as c-myc, CCND1 and DKK1 
(Supplemental Fig. S4A). Importantly, treatment of MCF7-10b cells with ICG-001 blocks proliferation 
and down regulates HMGA2 expression (Supplemental Fig. S4B-C and page 15, 1st paragraph). 
 
11. The authors used the MDA-MB-231 cells to test whether ICG-100 cause an induction of INK4 locus 
CDK inhibitors. These results are puzzling, particularly because there are several reports in the literature 
claiming that these breast cancer cells are INK4 locus deleted (i.e Bisonga et al Cancer Genetics and 
Cytogenetics 125 (2001) 131-138 and others). This locus includes p16, p19 and p15. Thus it is very 
strange that the authors do not observe activation of p16 and p19 but observe activation of p15. Given the 
literature reports, the authors must verify that their MDA-MB231 cells have an intact INK4 locus 
(including INK4b).  
Point by point response: We strongly regret this over site and thank the reviewer for this very important 
observation.  We have removed all references to INK locus from the MS. We have gone back to each 
experiment and discovered where the probable mistakes occurred in switching out the inappropriate cell 
line.  We are fortunate that this was solely for that INK locus western results and all of the qt-PCR 
conducted in that context.   We purchased some variants of MDA-MB cell lines from the ATCC to ensure 
we had the right phenotype with ICG-001 treatment (Fig. S4F) and we added the following to the text of 
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the manuscript and repeated many of the same experiments to ensure that we have the same results as the 
ATCC cell lines.  
“We further validated the effects of ICG-001 on various subtypes of TNBC cells lines, we 
purchased commercially from ATCC to ensure authenticity of the cell lines. ICG-001 treatment 
down regulated HMGA2 and two of its downstream targets CCNA2 and CCNB2 and BIRC5, 
which is a known direct target of ICG-001 in a subset of MDA-MB derived cell lines 
(Supplemental Fig. S4F) 
 
12. To determine if HMGA2 is necessary and sufficient for proliferation of MDA-231 cells downstream 
of WNT10b, the authors should test if WNT10b exogenous expression effect is completely abolished by 
shHMGA2.  
Point by point response: We thank the reviewer for these insightful comments and we think that the 
requested experiments have strengthened our manuscript substantially. 
i) We added two new sections to Fig. 5 (E,F) to address the above comment. 
ii) We added the following to the text of the MS: Page 19, 2nd paragraph” 
“To test our model for the order of action of genes in a regulatory hierarchy that governs the 
Wnt10b/beta-catenin signaling pathway, we designed an epistatic functional assay for WNT10B. We 
transfected MDA-MB-231 cells with pcDNA3-GFP and pcDNA3-WNT10B vectors, cells were harvested 
and qt-PCR was conducted for WNT10B, HMGA2 and CCNA2 (Fig. 5E). Concurrently, we repeated the 
previously mentioned transfection with our MDA-MB-231-shHMGA2 silenced verified cell lines (Fig. 
5F).  The results illustrate that WNT10B induced the expression of HMGA2 and is its known downstream 
target CCNA2 in control cells.  In contrast, cell lines silenced for HMGA2 can still express WNT10B but 
the expression of HMGA2 and its downstream target CCNA2 is lost.  The above experiment supports the 
epistatic activity of WNT10B on both HMGA2 and CCNA2 gene expression in triple-negative MDA-MB-
231 cells.” 
 
13. Given the same sample set was used to evaluate the differences in disease-free survival between 
groups that express low and high WNT10b and HMG2A, a correlation between the expression of both 
genes and its significance should be draw as this is pivotal to the author’s claims.  
Point by point response: We have utilized a Kendal Tau-b correlation coefficient analysis for the 
correlation between the two markers in our own 55 TNBC samples and as well for both beta-catenin and 
BMI-1 for another ongoing publication.  The results show that concurrence occurs in the paired analysis 
between the 4 markers.  The strongest correlation is between HMGA2 and BMI1 (0.80386) while 
WNT10b has an identical coefficient of correlation (0.79497) with both beta-catenin and HMGA2 (data 
not discussed in the manuscript). Please see above to reviewer #1 for the detail data for this point by point 
response for the eyes of the reviewers only. 
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Supplemental Figure 6 staining’s not comparable in terms of intensity, light and contrast.  
Point by point response: We have corrected this with Photoshop. 
Referee #2 (Other Remarks):  
 The triple negative breast cancer (TNBC) lacks targeted therapy. Identifying the critical pathways driving 
the growth of this type of breast cancers is a high priority in the breast cancer research field. The 
important role of the Wnt pathway in some of the TNBC has been implicated in several studies published 
in the past few years. The authors in the manuscript tried to demonstrate that the mouse MMTV-Wnt10B 
mammary tumor model mimics human TNBC. They further attempted to link the Wnt10B-induced 
canonical Wnt pathway to HMGA2 expression and the proliferation of cancer stem cells which they 
believed to be the CD44+ CD24+ cells. While the issue that the authors tried to address is important, the 
data presented are not convincing or lack proper controls. Some of the concerns are listed below:  
  
1. The authors concluded that WNT10B was strongly expressed in >60% TNBC based on IHC using a 
WNT10B antibody from Abcam (page 7 and Supplemental Material and Methods). The authors stated 
that that was the first time that WNT10B was detected in primary human breast tumors by IHC (page22). 
There are four antibodies against WNT10B from Abcam: ab70816, ab105860, ab66721, and ab91201 
(http://www.abcam.com/index.html?pageconfig=searchresults). Based on the company's website, both 
ab70816 and ab105860 recognize some unknown proteins based on Western blot, especially at 47kDa and 
93kDa regions, making them less specific to WNT10B. The ab66721 work for ICC 
(immunocytochemistry) but not IHC; and the ab91201 IHC staining signal is located outside the cells in 
several tissues, which is significantly different from the staining pattern seen in this manuscript. For these 
reasons, the detail information of the antibody used in this study and the positive/negative controls are 
critical for evaluating the result. Unfortunately, neither the specific antibody information nor the positive 
and negative controls can be found in this manuscript, making it difficult to evaluate the result. 
Furthermore, based on the Oncomine search, there is no significant difference of the WNT10B expression 
level between TNBC and non-TNBC. Therefore, the staining status of WNT10B in non-TNBC samples 
should be presented to show whether WNT10B is specifically expressed in the TNBC. This oncomine 
analysis should be discussed.  
Point by point response: We thank the reviewer for the thorough analysis of the WNT10B antibody and 
we completely agree with the concerns.  We have searched exhaustively for WNT10B antibodies over the 
years and we are excited about a WNT10B antibody from Abcam, catalog number Ab91201.  We 
apologize for the oversight of not listing it earlier.  We have done extensive serial dilutions with the 
antibody to optimize specific-labeling to help address this concern.  We purchased TMAs for the control 
requested for IHC. Illustrated in Fig. 1A are the majority of the TMA’s signature that is: negative for both 
ER+ and PR+ and some positive in the HER2+ tumors.  The few TN in the samples had a gradient of 
positive expression but all were well above the negative controls.  
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2. The authors claimed that the LacZ+CD44+CD24+ cells in the Wnt10bLacZ mammary tumor are a 
"stem-cell population" (page 11 and other pages). This claim lacks critical evidence. The limiting dilution 
transplantation assay is the only accepted method to demonstrate that a specific cell population is a stem 
cell population. This assay needs the transplantation of both the proposed stem cell population and the 
non-stem cell population. Only when the proposed stem cell population gives rise to tumor growth at a 
significantly higher frequecy than the non-stem-cell population, the proposed stem cell population can be 
concluded to be a stem cell-enriched population. Unfortunately, the authors only transplanted the 
LacZ+CD44+CD24+ cells without including the non-LacZ+CD44+CD24+ cell transplantation 
comparison.  
Point by point response: We thank the reviewer for these thoughts and we agree.  We have removed all 
references dealing with this topic from the manuscript. This area still requires more work in progress.  We 
have only utilized FACS-LacZ sorted cells from Wnt10bLacZ-induced primary tumors for in vitro assays 
for treatment with Wnt inhibitors. 
 
3. The authors demonstrated that the Wnt10b-driven tumors are TN tumors by showing ER, PR and 
Erbb2 negativity using qt-PCR (Fig2 and S3). Because the autors used pregnant mammary gland as a 
posittive contol, the relatively low mRNA level of ER or PR in the Wnt10b-driven tumors does not 
necessaryly mean that these tumors are ER/PR negative. IHC-based scoring on these tumors is necessary 
to evaluate whether these tumors are ER/PR negative. A similar problem is also true for concluding 
HER2 negativity.  
Point by point response: We now provide IHC-based evidence for the absence of ER-alpha, PR, and 
HER2 expression in Wnt10bLacZ-driven tumors (Fig. 2A).  We utilized wildtype mouse uterus tissue for 
controlling the ER-alpha and PR expression levels and the MMTV- ErbB2TG tumor for HER2 expression 
control. 
4. The authors tried to demonstrate "nuclear HMGA2 expression is restricted to TNBC as it was not 
detectable in ER-α+, PR+, Her2+ and TP breast cancer samples (Fig.6B)" (page 19). While they 
stated that 38 TNBC samples were used to demonstrate that greater more than 80% of them were positive 
for nuclear HMGA2, they did not show how many ER-α+, PR+, Her2+ and TP breast cancer 
samples were used for comparison. This is a very important concern because the Oncomine TCGA 
microarray data show no significant difference of the HMGA2 expression level between the TNBC and 
non-TNBC. There are many microarray datasets available in the Oncomine. Instead of chosing the large 
datasets such as the TCGA breast, the authors chose the relatively small dataset of Richardson to 
conclude that "HMGA2 is highly and specifically expressed in triple-negative (ER-PR-ErbB2-) human 
breast cancer". However, even in this dataset, the difference of HMGA2 expression between the TNBC 
and non-TNBC is not significant. Therefore, the authors' presentation of the analysis of public datasets 
was misleading.  
Point by point response:  We apologize for these concerns and we did not attempt to mislead on 
purpose.  We have removed all references for the Oncomine data and will in the future better understand 
its usefulness to present new arguments.  We now provide new evidence from our own collection of 
EMBO Molecular Medicine   Peer Review Process File - EMM-2012-01320
© EMBO 16
TNBC and from the KM-plotter, which shows that HMAG2 expression has clinical relevance for the 
basal-like breast cancer subtype (Fig. 6C , D). 
 
5. Stainings for nuclear beta-catenin, axin2, CK6 is not convincing.  
Point by point response:  Similar concerns were also mentioned by another reviewer. We thank the 
reviewers for this critique.  We understand the controversy over the relevance of beta-catenin in breast 
cancer, why is not always nuclear, if it is relevant?  To address this we: 
i) We have removed all of the co-staining from immunofluorescence experiments with 
beta-catenin, CK5, CK6, CK14 or CD44 from the manuscript. 
ii) 3 new AXIN2 IHC stainings (Suppl. Fig. S1B) from similar sequential tumor sections as 
in Fig. 1C were conducted. Taken together, we feel (Lugli et al, 2007)both the IHC and 
ISH for AXIN2 present evidence for active canonical Wnt signaling in the TNBC 
samples. 
iii) We undertook a set of experiments to alter the pH value of our samples and repeated IHC 
for beta-catenin utilizing further TN samples. In the revised manuscript we present 
evidence for both nuclear  (white arrows) and cytoplasmic (red arrows) beta-catenin (Fig. 
S1C).  Many cells are adjacent to each other that have both phenotypes. Published data 
for colorectal cancer and other studies on TNBC have shown that the overall content of 
nuclear and increased cytoplasmic beta-catenin varies between 5-80%in the tumor tissues 
(Geyer et al, 2011; Khramtsov et al, 2010; Lugli et al, 2007; Martensson et al, 2007; 
Wong et al, 2003)  Moreover, the distribution of nuclear beta-catenin throughout the 
tumor tissue is very heterogenous and often found at the invasive tumor front (Brabletz et 
al, 2005; Fodde & Brabletz, 2007) Our IHC staining results for beta-catenin confirm 
those observations (see also new Suppl. Fig.S8) and verify that nuclear beta-catenin can 
be detected in our TNBC patient samples verifying activated Wnt/beta-catenin signaling 
in these tumors. One of the sections corresponds to the IHC for AXIN2, which was 
illustrated above in ii (Fig. S1B).  
 
6. On page 3, the authors described "These breast cancers are divided into six subtypes that are highly 
heterogeneous both histologically (Weigelt & Reis-Filho, 2009) and by gene expression profiling (Perou 
et al, 2000; Sorlie et al, 2003)luminal A, luminal B, ERBB2/HER2, normal breast-like, basal-like and 
triple-negative (TN)." The terms used in the IHC-based clinical classification and the micro assay-based 
classification should not be mixed together.  
Point by point response:  We thank the reviewer for these thoughts and we agree that caution of terms 
must be made clearer in our manuscript.  We have added the following text to pages 6-7: 
“ It  is important to note that the molecular, clinical and pathological profiles of basal-like and TNBC are 
similar as they overlap by 60-90% (Al Tamimi et al, 2010); the terms are often interchangeable but they 
are not identical in their gene expression profiles leading to at least 6-8 complex subtypes (Perou et al, 
2000). So for this manuscript the term basal-like will be utilized when referencing microarray data (i.e. 
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mRNA ER-, PR- and HER2-) and the term TNBC will reference to analysis by pathologist who 
subsequently classified the tumors as ER-, PR-, HER2-  by IHC.  Triple-negative (TN) will be utilized to 
describe either basal-like and TNBC”. 
 
7. CD61 and Sca1 are not MaSC marker (page 8).  
Point by point response: We have removed all of the stem cell data and discussions from the manuscript. 
 
8. The rationale of the comparison of mammosphere-forming frequency between normal mammary gland 
cells and tumor cells is not clear (page 12).  
Point by point response: We have modified this section and have made changes to better reflect our 
rationale.   
i) To explain our rationale better, our new data illustrates that HMGA2 is lost in the Wnt10bKO 
mouse (Fig. 2E) in the early embryo during mammogenesis.  We then illustrate our 
mammosphere-forming frequency to test between gain-of-function cells (Wnt10bLacZ-derived 
tumor cells) and loss-of-function cells (Wnt10bKO-derived mammary cells) for “self-renewal” 
(Fig. 2F) and that tumor spheres correlate with expression of Hmga2.  Finally, we utilize the 
mammosphere-forming assay again using primary tumor cells (Fig. 3H-J) to block their 
formation with the Wnt-inhibitors ICG-001 and Wnt-C59. 
 
9. Some of the citations in text and bibliography are not formatted well or incomplete.  
Point by point response:  We apologize for the oversights and have updated our bibliography to correct 
this.  
 
Referee #3 (Other Remarks):  
The manuscript by Wend et al. reports on the role of Wnt signalling in triple negative breast cancer by 
making use of interesting mouse models and of primary human material. Overall, I found that, although it 
relies on previous evidence on the role of Wnt in TNBC and as such it is not entirely novel, it contains 
several advancements in our knowledge of the underlying cellular and molecular mechanisms and in 
particular on the role played by WNT10B as a ligand and of HMGA2 as a downstream effector. Having 
said that, the manuscript is excessively long as it encompasses a rather extensive body of experimental 
evidence presented in a confusing fashion that makes it extremely difficult for the reader to go through. 
Also, too often statements are based on "data not shown" and the rationale for a number of experiments 
has not been explained. In view of this, I'd propose major revision of the manuscript along the lines of my 
specific comments listed here below.  
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1. Page 6-7. The panel of 14 (German) and 24 (US) primary TNBCs samples is rather limited and, ideally, 
larger cohorts should be employed to validate the observations on WNT10B expression. Also, the 
evidence relative to cells earmarked by nuclear beta-catenin localization is central to this manuscript but 
is, somewhat surprisingly, not presented (data not shown). The IHC images presented in Fig. 1A, 
especially with Ab's directed against beta-catenin are not convincing and nuclear beta-catenin is not 
evident. As it is generally known, IHC analysis of beta-catenin subcellular localization is tricky and 
antigen retrieval protocol based on neutral pH should be preferred. From the images in my possession, 
strong (overstained?) cytoplasmatic staining is seen which makes it difficult to evaluate nuclear 
expression. The IF-based evidence for the co-localization of nuclear beta-cat with basal epithelial markers 
and CD44 (Fig. S1B-C) is also not very convincing and again this might be due to the poor graphic 
resolution of the figures in my pdf file. Also, CD44 is here mentioned as a "stem cell marker" with no 
references to back this up. To the best of my knowledge, although there are reports on the use of CD44 to 
enrich (cancer) stem cells (when combined with other CD markers) in specific tissues, CD44 is more 
often expressed in progenitor cells.  
Point by point response:  We thank the reviewer for this critique.  We understand the controversy over 
the relevance of beta-catenin in breast cancer, why is not always nuclear, if it is relevant?  We have 
worked on this and have improved the nuclear staining for beta-catenin in our TNBC samples. 
i) We have added new data on nuclear beta-catenin and AXIN2 expression (Suppl.  Fig. 
S1C,D) showing subcellular (red arrowhead) and nuclear (white arrowhead) localization. 
ii) We have removed all data from CD44, CK5, CK6 and CK14 from the manuscript. We 
have focused the revised manuscript on the question how Wnt10b mechanistically 
regulates HMGA2 and the role of HMGA2 on proliferation. 
iii) We have validated the expression of WNT10B in multiple control breast cancer subtypes 
(see below). 
 
2. Pages 7-8. I admittedly am not an expert on this but the data relative to WNT10B as a predictor of 
survival outcome (Fig. 1C-D) do not appear to be very strong. Again, important data to support this 
concept (LRP6 as a predictor and the specificity of WNT10B for TNBC but not for ER-a-
positive breast cancers is stated but not presented (data not shown). Overall, the conclusive paragraph at 
page 8 contains a number of rather hard conclusions which are not entirely supported by the experimental 
evidence (also the evidence relative to AXIN2 expression is not particularly convincing (Fig. 1A; also in 
view of the scarcity of specific Ab's capable of recognizing AXIN2 in IHC) and which should be 
tempered.  
Point by point response:  We thank you for your critique and have made major changes to address the 
concerns. 
i) IHC for WNT10B expression has now been conducted on 125 samples from TMA 
analysis with multiple breast cancer subtypes to better assess expression (Fig. 1A,B).   
ii) We have increased our own sample collection to include 31 TNBC with complete clinical 
data and 28 with partial clinic data and illustrate the clinical relevance for WNT10B (Fig. 
1C). 
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iii) We have identified a basal-like (i.e. TN) data base from KM-plotter illustrating that 
WNT10B can have predictive value. 
iv) We provide new AXIN2 IHC in TNBC. We have tempered our argumentation of our 
results throughout the manuscript. 
3. Page 8-9. To analyse the expression of MaSC markers in Wnt10b-driven tumors qt-PCR and IHC 
(again as data not shown) analysis is employed. However, the markers employed were originally found to 
enrich for MaSCs primarily by FACS analysis when employed in specific combinations 
(e.g.CD29hiCD24+). As such, it is difficult to interpret the significance of these results. Instead, I would 
have expected a thorough FACS analysis of these mouse tumors coupled with limiting dilution 
transplantation assays in immune-deficient or syngeneic hosts. Also, the sentence on CD44+CD24-/low 
in human TNBC (page 9) appears as "out of the blue" and not so relevant to this section of the result. In 
general, these type of comments which entirely rely on previous literature should be confined to the 
Discussion section.  The transplantation assays performed with Lin-Lacz+ tumour cells have been 
performed with extremely high number of cells (Fig. S2B-C; >0.5*106) and are not informative relative 
to their identity as CSCs or tumour-initiating cells. Also in this case, the data relative to 
Lacz+CD44hiCD24hi transplantation are not shown and it is not clear what the rationale was to prefer 
this specific combination of CD markers to. 
Point by point response:  We thank you for your critique and have made major changes to address the 
concerns. For this whole section on MaSC markers and FACS analysis of CD44CD24 tumor cells we 
completely agree with you and the other reviewers.  We do not have complete limiting dilution assays to 
argue for a CSC phenotype. All data dealing with this topic have been removed from the revised 
manuscript. 
 
 4. Page 10. To characterize (quantify?) Lacz+CD44hiCD24hi tumor cells, FACS analysis was employed 
(Fig. 2D). This part is unclearly written and I had difficulties in understanding what was actually done. 
The figure shows 3 distinct FACS panels relative to Lin-Lacz+ (tumour) cells (i.e. not 
Lacz+CD44hiCD24hi as stated in the text) with no indication to what they represent (not even in the 
legend). From the text, with some guessing, one infers that, from left to right, they show normal 
mammary gland cells from wild type and a transgenic Wnt10bLacz mice, and tumour cells from Wnt10b-
driven tumors. Provided my interpretation is correct, it is not clear what the significance of these analyses 
is in the absence of transplantation assays (at limiting cell multiplicities) for each of these subpopulations. 
Once again, the rationale for the choice of CD24 and CD44 instead of other previously established 
combinations of CD markers is unclear. In the last paragraph, it is stated that the expression of specific 
Wnt targets was in fact lower in Lacz+CD44hiCD24hi tumor cells when compared with Lacz+ and bulk 
tumour cells. This is surprising as it indicates a lower level of Wnt signalling in the alleged CSC 
population. These data should be confirmed by Wnt reporter assays rather than by evaluation of few 
downstream targets. This is also partly contradictory with the co-localization of these stem cell markers 
and nuclear beta-catenin.  
Point by point response:  We thank you for your critique and have made major changes to address the 
concerns. As previously stated we have removed the whole bulk of data and discussion on the tumorgenic 
cell in our model.  We have conducted extensive analysis in our tumor model for the known mammary 
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gland associated markers (CD44, CD24, CD29 and CD49f) in the LacZ+ cells and they are all present 
with complex interaction that are not well characterized yet. So we removed this and focus the manuscript 
on Wnt10b regulation of HMGA2 and its role on proliferation. 
5. Page 11. When it comes to Hmga2 expression, it is notable that this is highest in the bulk (unsorted) 
tumour cells when compared to all other subpopulations. Again, this questions the relationship between 
Wnt signalling, nuclear beta-cat and cancer stemness, also in relation to Hmga2 expression. Notably, 
Hmga1 is mostly expressed in Lacz+CD44hiCD24hi tumor cells but this observation is somewhat left 
unnoticed and is not followed up any further. From this perspective, the conclusive statement of this 
paragraph according to which Hmga1 and Hmga2 expression is increased in the stem-cell population is 
true only for the former but not for the latter.  
Point by point response: We completely agree with the critique and have made a major change in our 
experimental lineage-dump strategy to address the concerns. 
i) We have used a new kit from Stem Cell Technologies to improve our linage-dumping 
(MG Stem Cell Enrichment cat# 19757) and repeated the qt-PCR for Hmga2 (i.e. Lin-
LacZ+ cells) (Fig. 2C). The results illustrate that LacZ+ cells express as much Hmga2 as 
the sorted primary tumor cells and it is about 2-fold over that of Hmga1 in the same cells. 
We also compared the above to virgin mammary gland and ErbB2 tumors. 
ii) We have new data that HMGA2 levels are decreased in the Wnt10bKO mouse during the 
early stages of mammogenesis (Fig. 1E). 
 
6. Page 12. The mammosphere assays were performed with bulk tumour (and normal) cells and as such 
are not very informative. Preferably, FACSorted subpopulations of tumour cells should have been 
employed under controlled experimental conditions (limiting cell multiplicities in matrigel).  
Point by point response: We have repeated some of the mammosphere assays to make more informative 
insight into the mechanism for maintenance of the spheres. We FACS sorted (Lin-LacZ+) (Fig. 3H,I) and 
exposed them to the Wnt–inhibitors ICG-001 and Wnt-C59.  We illustrate that sphere formation requires 
both upstream Wnt-ligand and downstream beta-catenin signaling. 
7. Page 19. The data relative to the high (>80%) frequency of nuclear HMGA2 expression in TNBCs is 
again presented as "data not shown". Also, it is said that many of these TNBC were in fact metaplastic 
breast cancers and as evidence for that H&E staining is presented (Fig. 6A and SA-C). Metaplasia should 
be confirmed by IHC with specific markers for squamous or other "illegitimate" differentiation lineages. 
To the best of my capacity to analyse the figures (with the previously mentioned limitation of the poor 
graphic resolution) the images do not support this.  
Point by point response: We have toned down the use of metaplastic breast cancer because we did not 
have sufficient time to provide evidence by specific markers.  We utilize the terminology based on the 
report of the pathologists who scored and helped us analyzing the data. They also utilize the images from 
the H&E staining that phenotypically illustrates differentiated cells that look chondrocyte-like with large 
nuclei (Fig. 1A and Suppl. Fig. S1A-C). 
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 8. Pages 21-25. In view of my general introductory comments, the lengthy discussion should be shortened 
considerably.  
Point by point response: We thank the reviewer for these comments and we completely agree.  
i) We have made a major revision to the manuscript based on the recommendations from 
several of the reviewers to shorten results, discussions and data presentation. 
ii) The discussion has been shortened considerably. 
 
9. Page 23. "...we also provide evidence that Wnt10b-driven tumors are highly enriched in 
Lacz+CD44hiCD24hi cells that have cancer-initiating capacity when serially passaged in syngeneic mice 
(data not shown)". These data are indeed not shown throughout the manuscript and as such the authors 
cannot make this claim! Likewise, self-renewal assays (repeated cycles of CSC sorting by FACS, their 
transplantation at limiting dilution thus demonstrating not only their self-renewal but also their capacity to 
differentiate and recapitulate the primary tumors) were never formally performed. In this page, self-
renewal of CD44+ cells (?) is implied but was never shown. Likewise, in the follow-up of this discussion, 
it is suggested that CD44+ cells from TNBC tumors may be enriched in CSCs but the evidence for this is 
limited to immortalized cell lines resembling TNBC and not to primary patient material.  
Point by point response: We thank the reviewer for these comments and we completely agree.  
i) We have completely removed all the data from CD44CD24 cell- based self-renewal and 
cancer initiation because of the lack of convincing data.  
 
Overall, I believe that the evidence relative to WNT10B and HMGA2 expression and their downstream 
effectors in mouse and human TNBCs is novel and of general interest. However, when it comes to cancer 
stemness, its relationship with Wnt signalling, and the identification of a specific subpopulation of TNBC 
cells the evidence is much weaker and in part simply not shown or not appropriately performed. Given the 
value of the data on the functional role of to WNT10B and HMGA2 expression in TNBC, I would have 
preferred a shorter and easier to read manuscript with focus on these two genes, independently from the 
cancer stem cell aspects which are clearly less developed. Hopefully, my comments will be of help to the 
authors to improve their interesting manuscript.  
 
Point by point response:   
i) As suggested by the reviewer, we have now focused the manuscript on the functional role 
of WNT10B and HMGA2. 
ii) We provide mechanistic data (Fig 3 & 5). 
iii) We provide relevant data showing that WNT10B and HMGA2 expression have 
predictive value for TNBC (Fig. 1 &6). 
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iv) We used another Wnt-inhibitor (Wnt-C59) that block Wnt-ligand secretion. 
v) We have dramatically reduced the text.  
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2nd Editorial Decision 15 September 2012 
 
Thank you for the submission of your revised manuscript "WNT10B/β-catenin Signaling Induces 
HMGA2 and Proliferation in Metastatic Triple-Negative Breast Cancer" to EMBO Molecular 
Medicine. We have now finally received the reports from the reviewers who were asked to re-
review your manuscript.  
 
As you will see, the Reviewers acknowledge that the manuscript was improved during revision. 
However, they still raise concerns about the IHC quality and the interpretation of some results. Since 
we do acknowledge the potential interest of your findings, we would be willing to consider a revised 
manuscript with the understanding that the referee concerns must be convincingly and conclusively 
addressed.  
 
On a more editorial note, in your revised manuscript, please address the following points:  
 
- For experiments involving human subjects the submission must include a statement that informed 
consent was obtained from all subjects and that the experiments conformed to the principles set out 
in the WMA Declaration of Helsinki [http://www.wma.net/en/30publications/10policies/b3/] and the 
NIH Belmont Report [http://ohsr.od.nih.gov/guidelines/belmont.html]. Please see our Guide to 
Authors for further information and provide the necessary information in the respective Material and 
Methods part.  
 
- The description of all reported data that includes statistical testing must state the name of the 
statistical test used to generate error bars and P values, the number (n) of independent experiments 
underlying each data point (not replicate measures of one sample), and the actual P value for each 
test (not merely 'significant' or 'P < 0.05').  
 
- In addition, we noted that the resolution of some figure panels (including the IHC panels) is rather 
low and that the contrast of some panels (for example Fig 4G) should be improved. Please include 
higher resolution pictures and note that immunoblots should be surrounded by a black line to 
indicate the borders of the blot, if the background is faint (for example Fig 3G).  
 
- We noted that you included unpublished data in your point-by-point response. These would be 
published in a Peer Review Process File. Please let us know whether you agree with their 
publication, if you would like to delete the data from the file or if you would like to opt-out of 
having the PRPF published.  
 
I look forward to seeing a revised version of your manuscript as soon as possible.  
 
Yours sincerely,  
 
Editor  
EMBO Molecular Medicine 
 
***** Reviewer's comments *****  
 
Referee #1 (Remarks):  
 
The authors have adequately addressed, clarified or provided reasonable explanations to almost all 
of my concerns. Overall, the quality of the paper has improved; the flow of the manuscript eased and 
now the reader can identify a working hypothesis that is largely supported by the data.  
 
With regard to my major points, the authors have made an effort to provide strong clinical evidence 
to position their findings. Moreover, they have improved their statistical analysis particularly with 
regards to patient data analysis. The reader can now link the model of WNT10B with the expression 
of HMGA2, their mechanistic association. Most importantly, they have restricted their claims 
regardless the stem cell related matters posted in their previous manuscript version. These changes 
have largely reduced the noise within the text and streamline the message. Besides, most of the 
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 weakly supported data has been eliminated.  
 
Focusing on the mechanistic analysis the use of two independent Wnt-related inhibitors, the causal 
validation of HMGA2 downstream of WNT10b and others have strengthened the authors' claims. 
Finally, a proper re-evaluation of the MDA-231 data and the INK4 locus re-activation has been 
settled.  
 
Thus, the new data and comments provided are convincing. Moreover, the explanation and the 
unpublished disclosed information regarding point 3 does suffice. Finally, they have improved and 
upgraded the quality of the figures.  
 
Given all the above, the manuscript represents a substantial advance on the field pending on some 
remaining sticky points that must be addressed.  
 
1. Page 6, first paragraph, line 2-3. "the translation wnt10b model may provide a novel therapeutic 
tool to develop inhbitiors for stem cell-like cancers..." This affirmation is pure speculation, not 
supported at all by the data. The authors must refer to TNBC at most.  
 
2. Page 7, 4th line. "... on the TMA from Ohio were selected ..." . To define the origin of a TMA by 
stating "from Ohio" is not scientifically appropriate. Please refer to Ohio Tissue Bank Cohort or use 
acronym.  
 
3. Page 7, 6th line. The sentence "In contrast, the most of the TNBC..." contains too many "the"  
 
4. Page 7, last paragraph. It is not clear in which data set or patient cohort the statistics are 
calculated. Please clarify  
 
5. Page 8, last sentence 2nd paragraph. The sentence is not supported by the data since the authors 
do not clarify the unique causality and specificity of WNT10B for TNBC tumors (there are other 
Wnt-ligands) and no experimental data on preclinical mouse models is provided (i.e. WNT10b KO 
crossed with PyMT or Wnt-inhibitors blockade of WNT10B driven tumors in vivo). Thus, the 
sentence is pure speculation and should be contained in the discussion section.  
 
6. Page 21, 2nd paragraph, 3rd sentence. It is not clear which patients (data set, cohort etc) do the 
authors refer to. Please clarify.  
 
7. Pag 21, last paragraph. "In summary, we have presented evidence supporting that HMGA2 
expression is an important clinical marker ...". This sentence overstates the power of HMGA2. 
Clearly, the authors present clinical evidence of the capacity of HMGA2 to predict survival outcome 
in TNBC. Yet, this marker is not independent of other clinical variables currently used in the 
standard of care (Tumor size, nuclear grade or even Ki67). Thus, its importance is limited to the 
current research and the understanding of the TNBC biology. The authors must eliminate the word 
"important" prior to "clinical marker" since given the association with tumor size this marker 
currently does not have sufficient value to be implemented in the clinical setting, thus is not an 
important clinical marker.  
 
8. Page 23, 1st paragraph, 2nd line. "We demonstrate that this is due to the presence of WNT10B-
ligand...". This sentence is too strong since other Wnt-ligands cannot be excluded to contribute. 
Please re-phrase.  
 
9. Page 23, 1st paragraph, last sentence. The authors must clarify that the marker is not independent 
of other well-established markers to avoid any over interpretation by the readers.  
 
10. Page 24, 2nd paragraph. The authors enthusiastic interpretation of the potential application of the 
data should be tune down by clarifying that the need of testing this hypothesis in preclinical 
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 Referee #2:  
 
I am still not convinced. the antibody and staining specificity for wnt and beta-catenin as well as 
others is still a concern.  
 
 
2nd Revision - authors' response 26 October 2012 
 
(please see next page) 




















Thus, the new data and comments provided are convincing. Moreover, the explanation and the
unpublished disclosed information regarding point 3 does suffice. Finally, they have improved and
upgradedthequalityofthefigures.





















4. Page 7, last paragraph. It is not clear in which data set or patient cohort the statistics are
calculated.Pleaseclarify.

Pointbypoint response:Weclarified theaboveby addingour collectionof 59TNBC; it now
states “To this end we utilized the available clinical data from our collection of 59 TNBC 
samples,…”














Point by point response: We corrected the sentence and added “basallike” and “(Fig. 1E)” for
clarification; it now reads as follows:  “Remarkably, basallike patients with high HMGA2 mRNA
levels (80% of the patients) had a significant lower probability of survival than those with low
HMGA2 levels [logrank test P=0.0308, hazard ratio (HR) =2.0], albeit fewer patients passed the
criteriathanintheWNT10Banalysis(Fig.1E).”

7. Page 21, last paragraph. "In summary, we have presented evidence supporting that HMGA2
expression is an important clinical marker ...". This sentence overstates the power of HMGA2.
Clearly,theauthorspresentclinicalevidenceofthecapacityofHMGA2topredictsurvivaloutcome
inTNBC.Yet,thismarkerisnotindependentofotherclinicalvariablescurrentlyusedinthestandard
of care (Tumor size, nuclear grade or even Ki67). Thus, its importance is limited to the current
research and the understanding of the TNBC biology. The authors must eliminate the word
"important" prior to "clinical marker" since given the association with tumor size this marker













presenceofWNT10Bligand..."andreplaced itwith the following: “Additionally,wecorrelate the



















“Mechanistically, our data now provide evidence that WNT10B activates canonical catenin
signaling leading toproliferationandupregulationofHMGA2 inTNBCdirectlyby componentsof
the canonical Wnt signaling pathway.  Furthermore, the Wnt/catenin inhibitor ICG001 can











I am still not convinced. the antibody and staining specificity forwnt andbetacatenin aswell as
othersisstillaconcern.

COMMENTS:We thank the reviewer for raising the concerns in regards to the specificity of the
antibodiesusedforourcurrentmanuscript.Iwouldliketonoteatthistimethatwearetakingthe
concerns raisedby the reviewervery seriouslyandhavemadea tremendouseffort toaddressas
many of the concerns as possible (within the limits of the available antibodies used in the field).
Furthermore, toalleviate thereviewerconcernswehavesequentiallydilutedallof theantibodies
from1/25toasmuchas1/5000optimizingeachantibodiesspecificitywhileconcurrentlychanging
ranges of pH’s and optimizing buffers.We have now included as many controls to alleviate the
concernsfortheIHCofhumansamplesincludingcommerciallyavailableTissueMicroarrays(TMA’s)
with a wide range of breast cancer subtypes and “adjacentnormal breast tissue” from nearby
tumors.  We have conducted IHC experiments on various stages in embryonic development
contrastingwildtypeversusWnt10bknockoutmiceutilizingourantibodies.Forthepurposeofthis
manuscriptwehavefocusedonthedevelopmentofmousemammaryglandplacodesatembryonic
day E14.5. We now have utilized UCLA’s imaging core that has state of the art advanced light
microscopes incollaborationwithcoredirectorDr.LaurentBentolilatoimprovethequalityofour






1) Figure 1A. TMA’s have been reimaged for improvement of the resolution and improving
Wnt10bIHCcontrast.

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2) Figure 1C was reimaged with advanced lightmicroscopes for higher magnification




i)We conducted immunoblotting againstWNT10B protein expression highlighting
thestrongspecificityof theantibody (ab912015A7,Abcam) in transgenicprimary tumors
and a secondary syngeneically transplanted tumor vs. that of the established cell line
utilizedthroughoutourmanuscript(WZALacZ).Weobservednouppermobilitycrossreacting
bands but a very specific single band corresponding with the correct molecular weight
predictive forWNT10Bprotein (43 kDa). The reviewer raised concerns from the previous





all theWntligands (but known toexpress lower levels ofWnt10b). TheNMuMGWnt10b
overexpressingcelllinewasengineeredtoonlyexpress~2foldmoreWnt10bmRNAlevels











iv)To furtheralleviate concerns,we tested for the crossreactivityof theWnt10b
antibody by IHC in wildtype vs. Wnt10bknockout (Wnt10b/) embryos at E14.5.  We
illustrate specific cytoplasmiclocalization of WNT10B in wildtype mice in the epidermis




andalternatively Wnt7a and16) reviewedextensively (Wendet al, 2010). Our IHCdata
stronglysuggest thatotherWntligandsarenotcrossreactingwiththisparticularWnt10b
antibodybecauseweseenoIHCbackgroundstaininginWnt10b/mice.Thedilutionused











be fundamental for the disease. Nonetheless, several rationales have been provided for the
relevanceofWnt/cateninsignaling inbreastcancer that is supportedby the literature. Further
rationaletoinvestigatetheWnt/cateninpathwayinTNBCwasprovidedbyastudythatanalyzed
publically available data sets by gene expression profiling and robustly identified 548 TN breast
tumor datasets (Lehmann et al, 2011). The results illustrated that TN tumors are highly
heterogeneouscomprisingatleastsevensubtypes.Distinctgeneontologieswereutilizedtoidentify














results that we have optimized (by sequentially changing the pH and diluting the antibodies) to
enhancedetectionofnuclearlocalizationandtocontrastittoamonoclonalnonphospho(ACTIVE)
catenin(Ser33/37/Thr41)antibodyrecognizingonlyactivecatenin,whichisnotphosphorylated
(Cell Signaling, #8814).  In our new Supplemental Figure 8we compare and contrast TMAs from
different breast cancer subtypes (ER+, PR+, HER2+, and TriplePositive [TP]) to TNBC using two

















illustrate reduced stroma staining and greater nuclear and cytoplasmic localization
(yellowarrows)and inonesamplemostlynuclear localization (redarrows).When the
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activatednonphosphorylatedcateninantibody istestedagainstotherbreastcancer
subtypes (ER+,PR+ and TP+) it is substantially decreased and consistent with our
modeling.  In HER2+ breast cancer one can find mostly cytoplasmic nonphospho
cateninbutmuch less compared to thepanantibodyandmuch less than in theTN
tumors. This isagain consistentwithourmodeling inpublished literature. It is known
that a subclass of TN carries a Her2+Wnt signature and vice versa thus these results
wouldbeconsistentwithsomeexpressionlevelofAXIN2(Perou,2010).
iii) In Supplemental Figure 8C we reanalyzed and optimized the IHC for AXIN2
whichisknowntobeadirectWnt/cateningenetargetrepresentingtranscriptionally
activecatenin.Theresultsillustratethatothersubtypesofbreastcancershavelittle
or no expression of AXIN2 with the exception of HER2 tumors. Nonetheless, when
contrasted to either CRC or TN the levels of AXIN2 protein expression are high and
localizedtothecytoplasmforthemostpart.

We have further addressed the reviewer concerns about antibody staining and specificity by
providingbetterpicturesofourIHCresultsforthedetectionofERPR,HER2,andHMGA2.The




specific staining for ERPR andHER2 at higher resolutions (inserts 60X).  The colors
have been greatly improved to better reflect contrast in the nuclear stained cells vs.
negativestainedcellsthenourpreviousimages.
v) Figure2D (IHC forHMGA2);we reimagedwith theadvanced lightmicroscope
andchangedthecontrast tobetterreflectspecificlocalization.Dilutionsweredoneat
1/2500with2minutes development usingDAKOkits.Wehavearray data confirming
thatHMGA2 isthehighestregulatedgene inourmodel.Withthenewimageswecan
seegreaterspecific labelingofHMGA2as insomecells thebluenuclei isveryevident








































































3rd Editorial Decision 07 November 2012 
 
Thank you for the submission of your revised manuscript to EMBO Molecular Medicine. I am 
pleased to inform you that we will be able to accept your manuscript pending the following final 
amendments:  
 
The description of all reported data that includes statistical testing must state the name of the 
statistical test used to generate error bars and P values, the number (n) of independent experiments 
underlying each data point (not replicate measures of one sample), and the actual P value for each 
test (not merely 'significant' or 'P < 0.05').  
 
Also, please follow the instructions for submission of the revised form as described below where 
you have not done so before.  
 
Please submit your revised manuscript within two weeks. I look forward to seeing a revised form of 
your manuscript as soon as possible.  
 
Yours sincerely,  
 
Editor  
EMBO Molecular Medicine  
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